Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Wipro Limited (WIT) Price & Performance

AbbVie IncTrade
Wipro LimitedTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Wipro Limited — how do they compare? AbbVie Inc trades at $249.02 (market cap $438.19B), while Wipro Limited trades at $1.98 (market cap $19.22B). The key difference: AbbVie Inc is far larger — about 22.8× Wipro Limited's market cap, and Wipro Limited pays the higher dividend (4.35%). Which is the better fit depends on your goals.

ABBVWIT
Market Cap
$438.19B$19.22B
Sector
HealthTechnology
52-Week High
$263.58$3.06
52-Week Low
$197.38$1.78
Enterprise Value
$502.45B$17.30B
Dividend Yield
2.79%4.35%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $249.94, up 1.59% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats (Q4 2025 to Q2 2026) and a 70.73% buy rating from analysts highlight confidence. Revenue grew to $61.16B in 2025, though net margin dipped to 6.9%, while Skyrizi and Rinvoq drive growth post-Humira patent expiry. A dividend of $1.73 is scheduled for August 2026, supporting income appeal.

Outlook is positive with a $281.33 price target, but risks include high P/E of 70.05, patent cliffs in the 2030s, and regulatory lawsuits. Institutional buying and robust pipeline innovations like ELAHERE® in ovarian cancer offer upside, yet valuation and competitive pressures warrant caution for growth sustainability.

Wipro Limited

WIT trades at $2.02, up 1.51% today, with a neutral technical signal and bearish moving average trend. The company reported a net income margin of 13.92% and ROE of 16.09% for 2025, with revenue of $890.88 billion. Recent earnings have missed expectations, but partnerships with Databricks and ServiceNow aim to drive AI-led growth. Cash flow from operations remains strong at $169.43 billion, supporting a $0.02 dividend.

The outlook is mixed: valuation ratios like P/E of 15.25 and EV/EBITDA of 7.83 appear reasonable, but earnings misses and competitive pressures pose risks. Analyst sentiment is cautious with only 19% buy ratings. Key opportunities include AI expansion, while risks involve client spending cuts and margin pressure from wage increases.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Wipro Limited

Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.

Read more on WIT